

International Regulatory Collaboration: **Project Orbis Update**

R. Angelo de Claro, M.D.

Oncology Center of Excellence

US Food and Drug Administration

November 1, 2023




Presentation Outline

- Oncology Center of Excellence (OCE) and Global Collaboration
- Project Orbis Framework
- Project Orbis Update
- Challenges and Future Directions

FDA Oncology Center of Excellence (OCE)



The Oncology Center of Excellence fosters unified interaction between 3 FDA centers



- Established on January 20, 2017
- Authorized by 21st Century Cures Act: First FDA Inter-Center Institute

Office of Therapeutic Products (OTP)

- CAR-T and other cellular therapies, gene therapy, therapeutic vaccines

Office of Oncologic Diseases (OOD)

- small molecule drugs, monoclonal antibodies, antibody-drug conjugates

Office of In Vitro Diagnostics and Radiological Health

- diagnostic devices

Approvals Jan 2017 to Sep 2023:

96 new molecular entities (NME)
261 new indications
Average review time ~ 6 months

FDA Oncology Global Collaboration



- Began in October 2004 with European Medicines Agency (EMA)
- **Expanded Oncology Cluster to other Regulatory Authorities:**
 - January 2010: Health Canada (HC)
 - January 2014: Pharmaceuticals and Medical Devices Agency (PMDA) (Japan)
 - July 2014: Therapeutic Goods Administration (TGA) (Australia)
 - July 2016: Swissmedic (SMC) (Switzerland)
- **Project Orbis: Collaborative Review Program**
 - Launched in May 2019
 - Current participating countries (Project Orbis Partners): Australia, Brazil, Canada, Israel, Singapore, Switzerland, United Kingdom



Key Features of Project Orbis

- **Earlier submission of applications to Orbis countries**
 - within 1-2 months of FDA submission
- **Collaboration with other regulatory authorities**
 - Project Orbis teleconferences
 - Invitation to observe FDA standard processes and meetings
 - Assessment Aid document
 - **FDA:** formal review document
 - **Orbis countries:** core reference document

Key Features of Project Orbis



- **Leverages FDA staffing and expertise with application review**
 - **FDA Oncology Staff:** 280+ full-time (95 oncologists + 10 clinical analysts, 40 statisticians, 30 clinical pharmacologists, 35 nonclinical, 70 project managers)
 - **FDA Disease-Specific Teams: ~ 18**









Breast-Gynecologic (3)	Genitourinary (2)	Thoracic/Head-Neck (2)
Gastrointestinal (2)	Melanoma/Sarcoma	Pediatric/Neuro-oncology (2)
Leukemia/HSCT (3)	Lymphoma (2)	Myeloma
 - FDA review provides for independent multi-disciplinary assessment including full review of datasets.
- **Each country retains independent decision-making for each application**


Project Orbis Types



Orbis Type	Submission Timeline	Submission overlaps with FDA	Sharing of FDA reviews	Multi-country review meetings (POP TCONs)	POP Attendance at FDA review meetings	Concurrent review with FDA	Near concurrent action with FDA
Type A	≤ 1 month of FDA submission	Expected	Yes	Yes	Yes	Expected	Possible ¹
Type B	> 1 month of FDA submission	Expected	Yes	Yes	Yes	Possible	No
Type C	Any time after FDA submission	Permitted	Yes	No	Unlikely	Unlikely	No

Project Orbis: Dec 2022 Update

	Submitted	Action
FDA 	97	89
HC 	64	55
TGA 	65	47
SMC 	47	27
HSA 	32	22
ANVISA 	32	25
MHRA 	15	14
MOH 	17	12
Total	369	291





Project Orbis Highlights

- 80 unique “projects” in 3.5 years
 - 33% are NME NDAs (50% used PQAA) or Original BLAs
 - other applications: new indications (SE1), new dosage forms for pediatric population
- Median number of countries per application: 3
- ~ 40% of OOD NME/SE1 workload referred for Orbis
- Submission Gap to FDA: median 1.9 months
- Action Gap to FDA: median 5.8 months

Challenges and Future Directions



- **Logistical Challenges**
 - **Regulatory authorities:** review coordination and logistics (e.g., multiple time zones)
 - **Applicants/Sponsors:** concurrent submission and management of applications
- **Other Challenges:** expansion to other countries, translation requirements, operational considerations (e.g., review clock)
- **What's new in 2023?** EMA to participate as an observer

FDA Oncology Center of Excellence (OCE)




Mission

The mission of the OCE is to achieve patient-centered regulatory decision-making through innovation and collaboration.



Project




Optimus



Project Silver



Project Confirm



Project ASIATICA

FDA U.S. FOOD & DRUG ADMINISTRATION
INDUSTRY CENTER OF EXCELLENCE

Project Facilitate

Assisting healthcare providers with requests for access to investigational oncology products

DO YOU NEED HELP SUBMITTING A SINGLE PATIENT IND EXPANDED ACCESS (EA) REQUEST (ALSO KNOWN AS COMPASSIONATE USE) FOR A PATIENT WITH CANCER?

...FDA's Oncology Center of Excellence (OCE) can help:


- Locate IRB resources
- Find an EA contact for a drug/biotech company
- Complete Form FDA 3926

Phone: (240) 402-0004
 Email: OncProjectFacilitate@fda.hhs.gov www.fda.gov/oce

Patients: Talk to your healthcare provider to discuss whether expanded access is an appropriate option.




PROJECT SOCRATES



Project Orbis

Project Renewal



Project Community



Project Equity



Project Frontrunner




OCE RWE



Project Significant



Project Pragmatica



Project Catalyst



OCE PFDD

Summary

- Oncology is a highly active area of drug development.
- Global collaboration between regulatory authorities facilitates drug application submission and review.
- Important role of engagement with key stakeholders including patient groups, academia, industry, and regulators